The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Can daratumumab be used to treat refractory MM?
Shaji Kumar, MD, from the Mayo Clinic, Rochester, MN talks to us about potential treatments for patients with multiple myeloma (MM) who are refractory to both immunomodulatory drugs (IMiDs) and proteasome inhibitors. Daratumumab, which has been approved for treating MM and has been shown to be even more efficacious when combined with IMiDs, is currently a major therapy for MM but the outcomes of patients with refractory MM when treated with daratumumab is unknown, as detailed by Dr. Kumar. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
